Track market-moving stories before they get noisy

Aperture Investors disclosed a new position in Floor & Decor (FND 0.89%) as of March 31, 2026, acquiring 467,836 shares in a trade estimated at $30.44 million based on average quarterly pricing, according to a May 15, 2026, SEC filing.

What happenedAccording to a filing with the Securities and Exchange Commission dated May 15, 2026, Aperture Investors initiated a new position in Floor & Decor (FND 0.89%) during the first quarter. The firm acquired 467,836 shares, with an estimated transaction value of $30.44 million based on the period's average closing price. The quarter-end value of the stake was $23.77 million, reflecting both the purchase and subsequent share price movement.

What else to knowThis was a new position for Aperture, and as of March 31, 2026, Floor & Decor represented 3% of the fund's reportable U.S. equity AUM.Top holdings after the filing:NYSE:CAVA: $35.67 million (4.5% of AUM)NASDAQ:LIN: $33.32 million (4.2% of AUM)NYSE:ORA: $31.44 million (4.0% of AUM)NASDAQ:IDCC: $31.31 million (4.0% of AUM)NASDAQ:SITM: $30.32 million (3.8% of AUM)As of Friday, Floor & Decor shares were priced at $51.40, down 30% this past year and well underperforming the S&P 500, which is up 28% instead.Company OverviewMetricValuePrice (as of Friday)$51.40Market capitalization$5.6 billionRevenue (TTM)$4.68 billionNet income (TTM)$199.48 millionCompany SnapshotFloor & Decor offers hard surface flooring, including tile, wood, laminate, vinyl, and natural stone, as well as decorative and installation accessories.The firm operates a multi-channel retail and commercial distribution model, generating revenue through warehouse-format stores, design studios, and online sales.It serves professional installers, commercial businesses, and do-it-yourself customers across dozens of U.S. states.Floor & Decor is a leading specialty retailer in the home improvement sector, focused on hard surface flooring and related accessories. The company leverages a warehouse-format store footprint and e-commerce platform to provide a broad product assortment at competitive prices. Its scale and direct sourcing strategy enable cost advantages and a differentiated value proposition for both professional and retail customers.

What this transaction means for investorsThis purchase ultimately looks like a contrarian bet on a housing recovery because Aperture bought into a firm that is struggling in some ways while continuing to gain market share amid one of the toughest home-improvement environments in years.

Helping to illustrate that point, the latest quarter wasn't particularly pretty on the surface. Net sales slipped 0.7% to $1.15 billion, comparable-store sales fell 3.7%, and diluted earnings per share declined 18% to $0.37 as consumers pulled back on big-ticket purchases amid elevated mortgage rates.

But management's actions suggest confidence that the slowdown is cyclical rather than structural. CEO Brad Paulsen said the company's board authorized a new $400 million share repurchase program because management believes the current share price does not reflect Floor & Decor's long-term intrinsic value. The company also opened six stores during the quarter and still plans to open 20 new warehouse locations in 2026 as it works toward a long-term goal of 500 U.S. stores.

Ultimately, if housing turnover eventually normalizes and renovation activity rebounds, Floor & Decor could emerge from this downturn with a larger footprint, greater market share, and a stronger earnings base than it had going in.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cava Group and SiTime. The Motley Fool recommends Linde. The Motley Fool has a disclosure policy.

ATLANTA--(BUSINESS WIRE)--Floor & Decor (NYSE: FND), the leading high-growth retailer specializing in hard-surface flooring for homeowners and professionals, today announced the grand opening of its newest warehouse store and design center in Schererville, Indiana, located at 1516-30 U.S. 41. The Schererville store will open with a team of approximately 40 associates and is led by Michael Albro, the store's Chief Executive Merchant. Floor & Decor operates more than 275 warehouse-format.

Here are three stocks with buy rank and strong income characteristics for investors to consider today, May 4th:

LyondellBasell Industries (LYB - Free Report) : This company which, is among the leading plastics, chemical and refining companies globally with operations across 18 countries, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 88.2% over the last 60 days.

This Zacks Rank #1 (Strong Buy) company has a dividend yield of 3.7%, compared with the industry average of 1.6%.

Crescent Energy Company (CRGY - Free Report) : This independent oil and natural gas company, which acquires, explores, develops, exploits and produces crude oil and natural gas properties principally in the shallow waters of the Gulf of Mexico and onshore properties in Texas, Oklahoma, Louisiana and Wyoming in the United States, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 57% over the last 60 days.

This Zacks Rank #1 company has a dividend yield of 3.6%, compared with the industry average of 0.0%.

PHINIA Inc. (PHIN - Free Report) : This company, which is a global leader in the development, design, and manufacture of integrated components and systems that enhance performance, improve fuel efficiency, and reduce emissions across combustion and hybrid propulsion platforms, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.1% over the last 60 days.

This Zacks Rank #1 company has a dividend yield of 1.6%, compared with the industry average of 0.0%.

See the full list of top ranked stocks here.

Find more top income stocks with some of our great premium screens

Here are three stocks with buy rank and strong value characteristics for investors to consider today, May 4th:  

Ring Energy (REI - Free Report) : This company, which is engaged in the exploration and development of oil and gas, carries a Zacks Rank #1 (Strong Buy), and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 233.3% over the last 60 days.

Ring Energy has a price-to-earnings ratio (P/E) of 6.17 compared with 17.20 for the industry. The company possesses a Value Score of A.

Crescent Energy Company (CRGY - Free Report) : This independent oil and natural gas company, which acquires, explores, develops, exploits and produces crude oil and natural gas properties principally in the shallow waters of the Gulf of Mexico and onshore properties in Texas, Oklahoma, Louisiana and Wyoming in the United States, carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 57% over the last 60 days.

Crescent Energy Company has a price-to-earnings ratio (P/E) of 6.36 compared with 20.60 for the industry. The company possesses a Value Score of A.

Prog Holdings (PRG - Free Report) : This company, which is a provider of lease-purchase solutions through e-commerce merchants, carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 8.1% over the last 60 days.

Prog Holdings’ has a price-to-earnings ratio (P/E) of 7.96 compared with 11.70 for the industry. The company possesses a Value Score of A.

See the full list of top ranked stocks here.

Learn more about the Value score and how it is calculated here.

HOUSTON--(BUSINESS WIRE)--Crescent Energy Company (NYSE: CRGY) (“Crescent” or the “Company”) today announced financial and operating results for the first quarter 2026. Crescent's earnings release and supplemental earnings presentation can be found at www.crescentenergyco.com. The Company's first quarter 2026 conference call is planned for 10 a.m. CT (11 a.m. ET) on Tuesday, May 5, 2026. About Crescent Energy Company Crescent is a differentiated energy company committed to delivering value thro.

For the quarter ended March 2026, Crescent Energy (CRGY - Free Report) reported revenue of $1.18 billion, up 24.5% over the same period last year. EPS came in at $0.53, compared to $0.56 in the year-ago quarter.

The reported revenue represents a surprise of +0.31% over the Zacks Consensus Estimate of $1.18 billion. With the consensus EPS estimate being $0.39, the EPS surprise was +34.76%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Crescent Energy performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Average daily net sales volumes - Total: 341 millions of barrels of oil equivalent per day versus 333.61 millions of barrels of oil equivalent per day estimated by three analysts on average.Average daily net sales volumes - Oil: 140 millions of barrels of oil per day compared to the 137.07 millions of barrels of oil per day average estimate based on three analysts.Average daily net sales volumes - Natural gas liquids: 77 millions of barrels of oil per day versus the three-analyst average estimate of 71.29 millions of barrels of oil per day.Average daily net sales volumes - Natural Gas: 743 millions of cubic feet per day versus 751.4 millions of cubic feet per day estimated by three analysts on average.Average sales price per mcf - Natural gas (before effects of derivative settlements): $2.37 compared to the $2.87 average estimate based on two analysts.Average sales price per bbl - Natural gas liquids (before effects of derivative settlements): $18.05 compared to the $20.02 average estimate based on two analysts.Average sales price per bbl - Oil (before effects of derivative settlements): $71.00 versus the two-analyst average estimate of $69.90.Revenues- Midstream and other: $6.04 million versus $20.75 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -83% change.Revenues- Oil: $893.32 million compared to the $839.68 million average estimate based on two analysts. The reported number represents a change of +44.2% year over year.Revenues- Natural gas liquids: $125.11 million compared to the $127.96 million average estimate based on two analysts. The reported number represents a change of +16.3% year over year.Revenues- Natural gas: $158.37 million versus the two-analyst average estimate of $199.21 million. The reported number represents a year-over-year change of -15.5%.View all Key Company Metrics for Crescent Energy here>>>

Shares of Crescent Energy have returned +0.2% over the past month versus the Zacks S&P 500 composite's +10% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.

Crescent Energy (CRGY) reported a loss due to noncash impairment charges driven by weak commodity prices and hedge losses. CRGY's acquisition strategy targets properties from higher-cost operators. CRGY then aims to optimize and lower costs over time. Free cash flow and EBITDAX improved.

Crescent Energy (CRGY - Free Report) closed the last trading session at $13.54, gaining 7.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $17 indicates a 25.6% upside potential.

The average comprises 13 short-term price targets ranging from a low of $13.00 to a high of $20.00, with a standard deviation of $2.31. While the lowest estimate indicates a decline of 4% from the current price level, the most optimistic estimate points to a 47.7% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.

But, for CRGY, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.

Price, Consensus and EPS Surprise

Here's What You May Not Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.

While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?

They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.

However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.

That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.

Why CRGY Could Witness a Solid UpsideAnalysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 20.5%, as three estimates have moved higher compared to no negative revision.

Moreover, CRGY currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Therefore, while the consensus price target may not be a reliable indicator of how much CRGY could gain, the direction of price movement it implies does appear to be a good guide.

On May 7, 2026, Liberty Mutual Foundation Inc, a 10% Owner, disclosed the sale of 32,600,000 shares of Crescent Energy Company (CRGY +1.79%) common stock for a total consideration of ~$401.96 million, according to a SEC Form 4 filing.

Transaction summaryMetricValueShares sold (direct)32,600,000Transaction value$402.0 millionPost-transaction shares (direct)4,213,628Post-transaction shares (indirect)80,783Post-transaction value (direct ownership)$52.4 millionTransaction value based on SEC Form 4 reported price ($12.33).

Key questionsHow substantial was the reduction in Liberty Mutual Foundation Inc.'s direct stake in Crescent Energy Company?
The direct position was reduced by 88.36%, with direct holdings falling from 36,894,411 to 4,213,628 shares, reflecting a material decrease in ownership concentration.What is the composition of Liberty Mutual Foundation Inc.'s remaining ownership and does it involve indirect entities?
After the sale, the insider holds 4,213,628 shares directly and 80,783 shares indirectly, with indirect shares attributed to related entities as detailed in the filing's footnotes; no derivative securities or options remain outstanding.Did this transaction affect Liberty Mutual Foundation Inc.'s overall exposure to Crescent Energy Company?
The sale substantially reduced exposure, but meaningful ownership persists via both direct and indirect Class A Common Stock holdings, totaling 4,294,411 shares as of the filing.Was the transaction driven by routine liquidity or portfolio management factors?
Given the single large block trade and absence of a 10b5-1 plan or historical cadence, the activity appears to reflect a strategic portfolio adjustment rather than scheduled liquidity management.Company overviewMetricValuePrice (as of market close 5/7/26)$12.33Market capitalization$4.20 billionRevenue (TTM)$3.81 billionDividend yield5.67%* 1-year performance metrics are calculated using May 7, 2026, as the reference date.

Company snapshotProduces and sells crude oil, natural gas, and natural gas liquids, with operations spanning the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con basins in the United States.Operates an asset-driven business model focused on exploration, development, and production of hydrocarbons from a diversified portfolio of proven reserves and drilling locations.Crescent Energy Company is a Houston-based independent energy firm with a portfolio of oil and natural gas assets across multiple prolific U.S. basins.

What this transaction means for investorsInvestors often pay attention to insider sales, but often they’re just a matter of portfolio management, liquidity needs, or changes in allocation. Sales like this usually have little to do with a company’s outlook, and Liberty Mutual’s sale of Crescent Energy appears to fit this description.

Crescent Energy isn’t an exciting, high-growth investment. The company focuses on generating cash flow and returning capital to shareholders. Its free cash flow and dividend yield make it attractive for investors, and its management has done well with acquisitions and operational efficiencies.

The biggest caveat is that oil prices don’t always cooperate with energy companies’ plans. Particularly in the current economy, oil prices have been volatile and unpredictable. That means investor sentiment around the stock could shift quickly.

This doesn’t make Crescent a poor investment. Those who already have diversified portfolios and patient, long-term strategies may wish to give Crescent Energy a closer look. Conservative investors or those who get nervous when prices swing dramatically may prefer businesses with steady earnings and less exposure to the energy sector.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Here are three stocks with buy rank and strong value characteristics for investors to consider today, June 2:

Crescent Energy Company (CRGY - Free Report) : This explorer and producer of oil and natural gas carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing nearly 33% over the last 60 days.

Crescent Energy has a price-to-earnings ratio (P/E) of 4.85, compared with 16.50 for the industry. The company possesses a Value Score  of A.

Pelagos Insurance Capital Limit (PLGO - Free Report) : This insurance and reinsurance company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 14.9% over the last 60 days.

Pelagos Insurance has a price-to-earnings ratio (P/E) of 5.72, compared with 10.10 for the industry. The company possesses a Value Score of A.

Gold.com, Inc. (GOLD - Free Report) : This precious metals company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 22.4% over the last 60 days.

Gold.com has a price-to-earnings ratio (P/E) of 7.97, compared with 8.90 for the industry. The company possesses a Value Score of A.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Learn more about the Value score and how it is calculated here.

Crescent Energy (CRGY - Free Report) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.

The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.

As such, the Zacks rating upgrade for Crescent Energy is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.

Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Crescent Energy imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.

Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for Crescent EnergyThis oil and gas company is expected to earn $2.38 per share for the fiscal year ending December 2026, which represents no year-over-year change.

Analysts have been steadily raising their estimates for Crescent Energy. Over the past three months, the Zacks Consensus Estimate for the company has increased 85.4%.

Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of Crescent Energy to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

The proposed transactions may contain terms that could limit superior competing offers.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT)'s merger with Marine Products Corporation. Upon completion of the proposed transaction, MasterCraft shareholders will own 66.5% of the combined company. If you are a MasterCraft shareholder, click here to learn more about your legal rights and options.

Silicon Laboratories Inc. (NASDAQ: SLAB)'s sale to Texas Instruments for $231.00 per share in cash. If you are a Silicon shareholder, click here to learn more about your legal rights and options.

Marine Products Corporation (NYSE: MPX)'s sale to MasterCraft Boat Holdings, Inc. for $2.43 per share in cash and 0.232 shares of MasterCraft common stock for each share of Marine. If you are a Marine shareholder, click here to learn more about your rights and options.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5), the European biotechnology company focused on gene therapies for age-related diseases, has reported that positive safety and efficacy signals from its SLAB trial have been maintained three months after the initial dosing period, with no adverse events observed.

The SLAB (Sarcopenia and Longevity in Aged Beagles) trial is evaluating Genflow's proprietary SIRT6 centenarian gene therapy in aged dogs, targeting sarcopenia, the age-related loss of muscle mass and strength that also affects humans.

The company said improvements across multiple independent endpoints remained consistent with earlier observations reported in February 2026, while control animals continued to show expected age-related decline.

The therapy targets SIRT6, a gene associated with longevity that is found to be more active in centenarians, and is delivered via gene therapy to restore or enhance its function in ageing subjects.

The trial is ongoing, with all animals continuing to be monitored, and completion is anticipated at the end of July 2026.

Additional analyses, including methylation clock assessment, a method of estimating biological age at the cellular level, and muscle histology, the microscopic examination of tissue structure, are in progress and are expected to provide further mechanistic insight into the therapy's effects.

Chief executive Eric Leire said the follow-up data extended the company's understanding beyond initial efficacy and into persistence of effect.

"The consistency of improvements across multiple functional endpoints, together with the continued absence of safety concerns, strengthens our confidence that SIRT6 gene therapy is delivering a sustained biological impact," he said.

Genflow said it was engaging with prospective partners in the animal health sector to explore licensing, co-development and commercialisation opportunities for its SIRT6 platform.

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO, Dr Eric Leire, talked with Proactive about encouraging results from the SLAB (Sarcopenia and Longevity in Aged Beagles) trial, highlighting sustained efficacy and safety following treatment.

Leire explained that one of the most significant findings is the durability of the therapy’s effects. Even three months after stopping treatment, the benefits observed in the dogs have been maintained.

He noted, "We stopped administration three months ago... and that's exactly what we see, both in terms of safety and in terms of efficacy." This persistence is a key milestone for gene therapy, as it could shift treatment from a repeated or chronic approach to a potential one-time intervention.

The durability of response also has broader implications for other indications Genflow Biosciences Ltd is pursuing. Leire indicated that the results support expectations for similar long-lasting effects in future applications, including MASH.

While clinical endpoints are already showing promising outcomes, the company is awaiting additional data from blood analyses and biopsies to complement these findings.

These results could further validate the therapy’s impact, including potential reductions in biological age. The existing data has already enabled early discussions with animal health companies regarding potential partnerships.

Proactive: Eric, very good to speak with you. The results in three months look encouraging. But what's actually changing in these dogs day to day that tells you the therapy's working?

Dr Eric Leire: What we notice now is the duration of effect. We stopped administration three months ago, and it was important to see if the benefit we noticed at the end of treatment would be maintained. That's exactly what we see, both in terms of safety and in terms of efficacy. So it's very good news.

Proactive: You mentioned persistence of effects. Why is durability such a critical piece of the puzzle for a gene therapy like this?

Dr Eric Leire: It changes everything because for the customer, it could be one therapy where you gain long-term benefit, rather than a chronic treatment. In terms of cost and convenience, it makes a totally different product. We are very happy to see this duration of effect. It’s also very interesting for other indications we are pursuing, because it allows us, for example, for MASH, to think we will have the same kind of duration of effect after therapy.

Proactive: You're still four months from completing the trial. What key data points are you waiting on, and what would a strong result look like?

Dr Eric Leire: What we have now is mostly clinical endpoints that matter to dog owners. We still need blood analysis and biopsy analysis as complementary data. The clinical data is already very promising and allow us to start negotiations with animal health companies. We want to outsource the product. It will be a nice confirmation if we see a decrease in biological age in the treated group.

Proactive: Thank you very much for your time.

Wireless IoT leader delivers $214 million in revenue and non-GAAP EPS of $0.53

, /PRNewswire/ -- Silicon Labs (NASDAQ: SLAB), the leading innovator in low-power wireless, reported financial results for the first quarter, which ended April 4, 2026.

"The Silicon Labs team delivered a strong start to 2026 with revenue of $214 million and meaningful year-over-year improvements in both gross margin and profitability," said Matt Johnson, President and Chief Executive Officer.

"Over the course of the quarter we saw an acceleration in bookings with declining inventory positions at our distributors and end customers, led by our broad industrial business. Design win momentum continued during the first quarter, exceeding both our internal targets and our 2025 run rate, which was a prior record year for the company. This performance underscores the breadth and depth of our innovative product portfolio across end applications.

Our leading indicators point to both near- and long-term strength, with book-to-bill ratio at a multi-year high and two quarters of record design wins, reinforcing our conviction in Silicon Labs' durable growth trajectory. At the same time, our proposed merger with Texas Instruments continues to advance, and we remain focused on disciplined execution and delivering for our customers."

First Quarter Financial Highlights

Revenue was $214 million, up 20% year-over-year Industrial & Commercial revenue was $128 million, up 33% year-over-year Strength in electronic shelf labels and smart metering end applications Home & Life revenue was $86 million, up 5% year-over-year Medical end applications revenue grew by 21% year-over-year Results on a GAAP basis:

GAAP gross margin was 59.5% GAAP operating expenses were $144 million GAAP operating loss was $17 million GAAP effective tax rate was (16.1)% GAAP diluted loss per share was $(0.48) Results on a non-GAAP basis, excluding the impact of stock compensation, amortization of acquired intangible assets, acquisition-related costs, and certain other items as set forth in the below GAAP to Non-GAAP reconciliation tables were as follows:

Non-GAAP gross margin was 59.7% Non-GAAP operating expenses were $109 million Non-GAAP operating income was $18 million Non-GAAP effective tax rate was 18%, which is the expected long-term rate for the remainder of the year Non-GAAP diluted earnings per share was $0.53 Due to the announced pending acquisition of Silicon Labs by Texas Instruments, Silicon Labs has suspended providing forward-looking guidance.

About Silicon Labs

Silicon Labs (NASDAQ: SLAB) is the leading innovator in low-power wireless connectivity, building embedded technology that connects devices and improves lives. Merging cutting-edge technology into the world's most highly integrated SoCs, Silicon Labs provides device makers the solutions, support, and ecosystems needed to create advanced edge connectivity applications. Headquartered in Austin, Texas, Silicon Labs has operations in over 16 countries and is the trusted partner for innovative solutions in the smart home, industrial IoT, and smart cities markets. Learn more at silabs.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding Silicon Labs' current expectations, which are based on its current views and assumptions. The words "believe", "estimate", "expect", "intend", "anticipate", "plan", "project", "will", and similar phrases as they relate to Silicon Labs are intended to identify such forward-looking statements, although the absence of such words does not necessarily mean a statement is not forward-looking. These forward-looking statements include, but are not limited to, Silicon Labs' expectations regarding its near- and long-term strength and durable growth trajectory and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations that are expressed or implied herein. Among the factors that could cause actual results to differ materially from those in the forward-looking statements are the following: our ability to complete the merger with Texas Instruments within the time frame expected, or at all, as well as potential disruptions in our business and restrictions on our activities during the pendency of the merger; fluctuating changes in global trade policies, including the imposition of tariffs, duties, trade sanctions, or other barriers to international commerce; the impact of the current global memory chip shortage; the competitive and cyclical nature of the semiconductor industry; the challenging macroeconomic environment, including disruptions in the financial services industry; geographic concentration of manufacturers, assemblers, test service providers and customers in Asia that subjects Silicon Labs' business and results of operations to risks of natural disasters, epidemics or pandemics, war and political unrest; risks that demand and the supply chain may be adversely affected by military conflict (including in the Middle East, and between Russia and Ukraine), terrorism, sanctions or other geopolitical events globally (including in the Middle East, and conflict between Taiwan and China); risks that Silicon Labs may not be able to maintain its historical growth; quarterly fluctuations in revenues and operating results; difficulties developing new products that achieve market acceptance; risks associated with international activities (including trade barriers, particularly with respect to China); intellectual property litigation risks; risks associated with acquisitions and divestitures; product liability risks; difficulties managing and/or obtaining sufficient supply from Silicon Labs' distributors, manufacturers and subcontractors; dependence on a limited number of products; absence of long-term commitments from customers; inventory-related risks; difficulties managing international activities; risks that Silicon Labs may not be able to manage strains associated with its growth; credit risks associated with its accounts receivable; dependence on key personnel; stock price volatility; the impact of public health crises on the U.S. and global economy; debt-related risks; capital-raising risks; the timing and scope of share repurchases and/or dividends; average selling prices of products may decrease significantly and rapidly; information technology risks; cyber-attacks against Silicon Labs' products and its networks; risks associated with any material weakness in our internal controls over financial reporting; risks relating to compliance with laws and regulations; and other factors that are detailed in the SEC filings of Silicon Laboratories Inc. Silicon Labs disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. References in this press release to Silicon Labs shall mean Silicon Laboratories Inc.

Note to editors: Silicon Laboratories, Silicon Labs, the "S" symbol, and the Silicon Labs logo are trademarks of Silicon Laboratories Inc. All other product names noted herein may be trademarks of their respective holders.

Silicon Laboratories Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)

Three Months Ended

April 4,
2026

April 5,
2025

Revenues

$       213,500

$       177,714

Cost of revenues

86,502

79,937

Gross profit

126,998

97,777

Operating expenses:

Research and development

88,594

88,219

Selling, general and administrative

55,486

41,638

Operating expenses

144,080

129,857

Operating loss

(17,082)

(32,080)

Other income (expense):

Interest income and other, net

3,626

3,793

Interest expense

(232)

(284)

Loss before income taxes

(13,688)

(28,571)

Provision for income taxes

2,209

1,899

Net loss

$        (15,897)

$        (30,470)

Loss per share:

Basic

$          (0.48)

$          (0.94)

Diluted

$          (0.48)

$          (0.94)

Weighted-average common shares outstanding:

Basic

32,963

32,465

Diluted

32,963

32,465

Non-GAAP Financial Measurements

In addition to the GAAP results provided throughout this document, Silicon Labs has provided non-GAAP financial measurements on a basis excluding non-cash and other charges and benefits. Details of these excluded items are presented in the tables below, which reconcile the GAAP results to non-GAAP financial measurements.

The non-GAAP financial measurements do not replace the presentation of Silicon Labs' GAAP financial results. These measurements provide supplemental information to assist management and investors in analyzing Silicon Labs' financial position and results of operations. Silicon Labs has chosen to provide this information to investors to enable them to perform meaningful comparisons of past, present and future operating results and as a means to emphasize the results of core on-going operations.

Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures

(In thousands, except per share data)

Three Months Ended

April 4, 2026

Non-GAAP Income
Statement Items

GAAP

Measure

GAAP

Percent of

Revenue

Stock

Compensation

Expense

Intangible
Asset

Amortization

Acquisition-
Related Costs

Other Costs

Non-GAAP

Measure

Non-GAAP

Percent of

Revenue

Revenues

$ 213,500

Gross profit

126,998

59.5 %

$         442

$          —

$          —

$   —

$ 127,440

59.7 %

Research and development

88,594

41.5 %

11,416

2,295

—

664

74,219

34.8 %

Selling, general and
administrative

55,486

26.0 %

9,197

—

11,213

—

35,076

16.4 %

Operating expenses

144,080

67.5 %

20,613

2,295

11,213

664

109,295

51.2 %

Operating income (loss)

(17,082)

(8.0 %)

21,055

2,295

11,213

664

18,145

8.5 %

Three Months Ended

April 4, 2026

Non-GAAP Earnings (Loss)
Per Share

GAAP

Measure

Stock

Compensation

Expense*

Intangible

Asset

Amortization*

Acquisition-
Related
Costs*

Other

Costs*

Income

Tax

Adjustments**

Non-

GAAP

Measure

Net income (loss)

$  (15,897)

$     21,055

$       2,295

$      11,213

$     664

$       (1,668)

$     17,662

Shares Excluded Due to Net Loss

Diluted shares outstanding

32,963

585

33,548

Diluted earnings (loss) per share

$    (0.48)

$        0.53

*  Represents pre-tax amounts

**  Represents the application of an 18% non-GAAP tax rate

Silicon Laboratories Inc.

Condensed Consolidated Balance Sheets

(In thousands, except per share data)

(Unaudited)

April 4,
2026

January 3,
2026

Assets

Current assets:

Cash and cash equivalents

$       383,089

$       364,222

Short-term investments

55,767

79,400

Accounts receivable, net

77,120

64,513

Inventories

103,232

95,566

Prepaid expenses and other current assets

57,113

70,316

Total current assets

676,321

674,017

Property and equipment, net

131,821

128,643

Goodwill

376,389

376,389

Other intangible assets, net

20,836

23,130

Other assets, net

61,094

67,138

Total assets

$     1,266,461

$     1,269,317

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable

$         56,384

$         50,717

Deferred revenue and returns liability

9,822

5,359

Other current liabilities

66,273

87,711

Total current liabilities

132,479

143,787

Other non-current liabilities

35,448

31,112

Total liabilities

167,927

174,899

Commitments and contingencies

Stockholders' equity:

Preferred stock – $0.0001 par value; 10,000 shares authorized; no shares issued

—

—

Common stock – $0.0001 par value; 250,000 shares authorized; 32,968 and 32,955
shares issued and outstanding at April 4, 2026 and January 3, 2026, respectively

3

3

Additional paid-in capital

177,551

157,402

Retained earnings

920,917

936,814

Accumulated other comprehensive income

63

199

Total stockholders' equity

1,098,534

1,094,418

Total liabilities and stockholders' equity

$     1,266,461

$     1,269,317

Silicon Laboratories Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

Three Months Ended

April 4,
2026

April 5,
2025

Operating Activities

Net loss

$        (15,897)

$        (30,470)

Adjustments to reconcile net loss to net cash provided by operating activities:

Depreciation of property and equipment

6,047

6,248

Amortization of other intangible assets

2,295

5,437

Stock-based compensation expense

21,055

19,714

Deferred income taxes

1,153

(1,514)

Changes in operating assets and liabilities:

Accounts receivable

(12,608)

2,412

Inventories

(7,616)

22,098

Prepaid expenses and other assets

6,813

2,973

Accounts payable

3,387

9,234

Other current liabilities and income taxes

(7,415)

11,870

Deferred revenue and returns liability

4,463

3,405

Other non-current liabilities

3,257

(3,279)

Net cash provided by operating activities

4,934

48,128

Investing Activities

Purchases of marketable securities

—

(19,728)

Sales of marketable securities

—

10,005

Maturities of marketable securities

23,461

10,675

Purchases of property and equipment

(9,837)

(4,852)

Proceeds from capital-related government incentives

1,265

—

Net cash provided by (used in) investing activities

14,889

(3,900)

Financing Activities

Payment of taxes withheld for vested stock awards

(956)

(958)

Net cash used in financing activities

(956)

(958)

Increase in cash and cash equivalents

18,867

43,270

Cash and cash equivalents at beginning of period

364,222

281,607

Cash and cash equivalents at end of period

$       383,089

$       324,877

SOURCE Silicon Labs

Dual-Band EFR32FG28 Wireless SoC Enables Secure, Interoperable RF Mesh Networking for India's Smart Energy Meter Rollout

, /PRNewswire/ -- Comminent®, an innovator in next-generation IoT communication network platforms, and Silicon Labs (NASDAQ: SLAB), the leading innovator in low-power wireless, today announced a major milestone for India's smart grid infrastructure with the successful shipment of over 500,000 Wi-SUN-compliant communication modules powered by Silicon Labs' EFR32FG28 Wireless SoC.

The FG28 dual-band SoC from Silicon Labs supports sub-Ghz wireless protocols and Bluetooth LE.

Comminent's FG28-equipped module. Scaling Wi-SUN for India's Smart Grid Modernization
India's Revamped Distribution Sector Scheme (RDSS) is driving one of the world's largest infrastructure transformations. To support this ambitious smart meter rollout, the Bureau of Indian Standards (BIS) officially adopted the global Wi-SUN Field Area Network (FAN) specification (IEEE 2857-2021 and ISO/IEC/IEEE 32857:2026) as the national standard (IS 18010) for smart meter RF communication networks. This standardization ensures secure, interoperable wireless mesh networks for large-scale Advanced Metering Infrastructure (AMI), smart cities, and IoT applications.

"Comminent's 500,000-unit milestone highlights the growing adoption of Wi-SUN in large-scale deployments," said Ross Sabolcik, Senior Vice President of Product Lines at Silicon Labs. "We are proud to partner with Comminent to provide the robust, scalable, and highly secure underlying technology needed to support India's ambitious grid modernization efforts and deliver reliable connectivity to millions."

Solving Complex Deployment Challenges at Scale
Comminent's deep focus on solving India's complex deployment challenges is central to delivering scalable and reliable rollouts. As utilities move closer to real-time monitoring and grid resilience, interoperable and self-healing networks like Wi-SUN are functioning as the primary infrastructure for large-scale deployment.

"India's smart metering rollout is one of the largest infrastructure transformations, and this milestone reflects the growing shift toward scalable, utility-grade communication networks like Wi-SUN," said Amarjeet Kumar, Founder & CEO of Comminent. "Our collaboration with Silicon Labs strengthens our ability to deliver high-performance communication modules engineered for advanced smart grid deployments."

Built on the EFR32FG28 Wireless SoC for Resilient, Utility-Grade Connectivity
To meet these demands, Comminent's communication module is powered by Silicon Labs' EFR32FG28 Wireless SoC, architected specifically for large-scale smart grid and industrial IoT applications. The EFR32FG28 platform enables reliable, long-range connectivity in demanding field environments, offering key advantages including:

Optimized Dual-Band Connectivity: Combines a high-performance, long-range Sub-GHz radio optimized for India's RF environment with a 2.4 GHz Bluetooth LE radio for increased design flexibility. Resilient Processing & Infrastructure: Features a high-performance multi-core architecture with dedicated ARM cores for application processing, radio, and edge intelligence, complemented by ample memory to deliver robust mesh networking performance in dense urban and geographically distributed deployments. Enterprise-Grade Security: Powered by Silicon Labs' Secure Vault™ technology with PSA Level 3 certification, delivering secure key storage, anti-tamper capabilities, and advanced hardware cryptographic acceleration. This combination enables utilities to deploy scalable, secure, and future-ready Wi-SUN networks capable of supporting millions of endpoints. With capabilities proven in India's large-scale deployments, Comminent is expanding into global smart grid markets, including the United States, Japan, and emerging energy-transition regions.

To learn more about how Silicon Labs is powering the next generation of smart grids, explore the EFR32FG28 Wireless SoC and our Wi-SUN solutions.

About Comminent
Comminent Pvt Ltd, headquartered in Bengaluru, Karnataka, offers IPv6-compliant open standards-based machine-to-machine (M2M) communication solutions that are device agnostic and built to provide high reliability. The company's state-of-the-art device management platform is powered by AI/ML tools combined with edge-computing technologies to ensure faster decision-making and trigger control actions based on predefined policies. Comminent has proven expertise in large-scale IoT networks, providing a variety of communication solutions and engineering tools to silicon vendors, module and product OEMs, system integrators, and service providers.

About Silicon Labs
Silicon Labs (NASDAQ: SLAB) is the leading innovator in low-power connectivity, building embedded technology that connects devices and improves lives. Merging cutting-edge technology into the world's most highly integrated SoCs, Silicon Labs provides device makers with the solutions, support, and ecosystems needed to create advanced edge connectivity applications. Headquartered in Austin, Texas, Silicon Labs has operations in over 16 countries and is the trusted partner for innovative solutions in smart home, industrial IoT, and smart cities markets. Learn more at https://www.silabs.com.

SOURCE Silicon Labs

Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentation RASolute 302 data planned for submission to global regulatory authorities, including the U.S. Food and Drug Administration AACR 2026 presentations reinforce the breadth and strength of company's RAS(ON) portfolio, highlighting continued progress and novel approaches to RAS(ON) inhibition Strengthened financial position with financings totaling $2.2 billion in gross proceeds Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif.

REDWOOD CITY, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that The New England Journal of Medicine (NEJM) has published a report describing data from the Phase 1/2 clinical trial evaluating daraxonrasib, a RAS(ON) multi-selective inhibitor, in patients with previously treated metastatic RAS mutant pancreatic ductal adenocarcinoma (PDAC). The promising Phase 1/2 findings provided important insights supporting initiation of the company’s global, randomized Phase 3 registrational trial, RASolute 302. Revolution Medicines recently announced positive topline results from the RASolute 302 clinical trial showing an unprecedented overall survival benefit with daraxonrasib compared to standard of care cytotoxic chemotherapy, consistent with the Phase 1/2 single-arm observations.

“RAS mutations are a central driver of disease across multiple solid tumors, including particularly pancreatic ductal adenocarcinoma. There is significant room for improvement in outcomes over current standard of care -- cytotoxic chemotherapies that are not targeted to these underlying RAS cancer drivers,” said Alan Sandler, M.D., chief development officer of Revolution Medicines. “Data from the Phase 1/2 trial show that daraxonrasib demonstrated promising clinical antitumor activity and durable responses, with an acceptable safety and tolerability profile, in patients with previously treated metastatic RAS mutant PDAC. These results, along with those from our Phase 3 trial, RASolute 302, strengthen our confidence in daraxonrasib’s potential to establish an important new treatment option for patients with pancreatic cancer and other RAS-addicted cancers.”

The data published in NEJM reflect outcomes in the PDAC cohort from the RMC-6236-001 trial (NCT05379985), an open-label, multicenter Phase 1/2 trial evaluating daraxonrasib monotherapy in patients previously treated for metastatic solid tumors harboring RAS mutations.

In addition to RASolute 302, daraxonrasib is being evaluated in three other global Phase 3 registrational trials, including in patients with PDAC in earlier treatment lines and those with metastatic RAS mutant non-small cell lung cancer.

About Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma
Pancreatic cancer is one of the most lethal malignancies, characterized by its typically late-stage diagnosis, resistance to standard chemotherapy, and high mortality rate. In the U.S., recent estimates indicate that annually approximately 60,000 people are diagnosed with pancreatic cancer, and about 50,000 people will die from this aggressive disease.1

Due to the lack of early symptoms and detection methods, approximately 80% of patients are diagnosed with PDAC at an advanced or metastatic stage. It is the most common RAS-addicted malignancy of all major cancers, and more than 90% of patients have tumors that harbor RAS mutations.2 Metastatic PDAC remains one of the most common causes of cancer-related deaths in the U.S., with a five-year survival rate of approximately 3%.3,4

About Daraxonrasib
Daraxonrasib is an investigational, oral RAS(ON) multi-selective, non-covalent inhibitor that is not approved by any regulatory authority, including in the United States or Europe. The U.S. Food and Drug Administration (FDA) granted daraxonrasib Breakthrough Therapy Designation and Orphan Drug Designation for the treatment of patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) harboring G12 mutations. In addition, daraxonrasib was selected for the FDA Commissioner’s National Priority Voucher pilot program, which is intended to accelerate the development and review of therapies aligned with U.S. national health priorities.

Daraxonrasib is designed to target cancers driven by a broad range of common RAS mutations, including PDAC, non-small cell lung cancer (NSCLC), and colorectal cancer. In addition to the RASolute 302 trial, daraxonrasib is being evaluated in three other global Phase 3 registrational trials, including in patients with PDAC and metastatic RAS mutant NSCLC.

Daraxonrasib works by suppressing RAS signaling through inhibition of the interaction between both wild-type and mutant RAS(ON) proteins and their downstream effectors.

About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation statements regarding progression of clinical studies and findings from these studies, including the safety, tolerability and antitumor activity of the company’s candidates being studied and the durability of these results; dosing and enrollment in the company’s clinical trials; the company’s expectations regarding from clinical trials; and the potential of daraxonrasib to estalish a new treatment option for patients with pancreatic cancer or other RAS-addicted cancers. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ current stage of development, the process of designing and conducting preclinical and clinical trials, risks that the results of prior clinical trials may not be predictive of future clinical trials, clinical efficacy, or other future results, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company’s business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 5, 2025, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Revolution Medicines Media & Investor Contact:
[email protected]
[email protected]

____________________

1 Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi:10.3322/caac.21820

2Lee JK, Sivakumar S, Schrock AB, et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis Oncol. 2022;6(1);91. doi:10.1038/s41698-022-00334-z.

3Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: Advances and challenges. Cell. 2023;186(8):1729-1754. doi:10.1016/j.cell.2023.02.014

4American Cancer Society. Survival Rates for Pancreatic Cancer. Available at: https://www.cancer.org/cancer/types/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html. Accessed May 2026.

SummaryCompaniesFDA allows expanded access to Revolution Medicines' experimental pancreatic cancer drugOncologists face logistical hurdles and resource strain to enroll patients in early access programDrug targets mutation that occurs in 90% of pancreatic cancersMay 14 (Reuters) - U.S. cancer centers are scrambling to enroll patients in an early access program for a highly promising pancreatic cancer ​drug from Revolution Medicines (RVMD.O), opens new tab while they await what they hope will be a speedy FDA approval.

The Food and Drug Administration allowed the expanded access program on May 1, ‌less than three weeks after Revolution said the once-daily pill, daraxonrasib, doubled survival in a clinical trial of patients with advanced pancreatic cancer, among the deadliest of cancers with one of the lowest 5-year survival rates.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

The company had asked the FDA for permission to make it available free-of-charge for patients with previously treated pancreatic cancer that has spread to other parts of the body.

"The public caught wind of the FDA announcement... which has triggered a deluge of patient requests," ​said Dr. Daniel King, medical oncologist at the Zuckerberg Cancer Center of Northwell Health. "Cancer centers are all figuring out how to engage with our own institutions, opening up the protocols ​to provide access."

Oncologists said getting approval and managing the expanded access program will take time and require cancer centers to dedicate substantial resources outside of ⁠their usual operations.

The drug was one of the first products accepted by the FDA last year for its new expedited review process, and could potentially get approval a month or two after a complete ​application is filed.

Revolution Medicines CEO Mark Goldsmith, speaking on a conference call last week, did not give a time frame for a full FDA submission. "There's a full-throttle effort to do it," he said.

The Redwood ​City, California-based company said it has already experienced high demand for the drug and expects it to remain high throughout the early-access program.

"We are actively supporting physicians through this process with safe, compliant, and rapid patient access as our top priority," Revolution said in a statement.

"All requests must be initiated by a licensed treating physician and reviewed by an institutional review board," the company said, adding that it expects to be able to respond to requests ​from physicians within two business days of receipt.

A BREAKTHROUGH TO BUILD ONFormer Nebraska U.S. Senator Ben Sasse recently revealed that he has Stage 4 pancreatic cancer and told the CBS news program "60 Minutes" that ​he is taking the Revolution drug.

The drug, which targets a genetic mutation found in about 90% of pancreatic cancers, was shown in a clinical trial to extend median survival to 13.2 months compared with 6.7 months for patients ‌on chemotherapy.

"Doubling ⁠survival compared to best available chemotherapy is a big deal," said Dr. Gulam Manji, co-director of the pancreas center at Columbia/New York-Presbyterian. "It is not a cure, but I think that this drug is a new breakthrough we can build on."

In a 10-year career, Manji could recall seeking compassionate use of an experimental drug for just one other patient. On a recent day in the clinic, the Columbia oncologist said seven patients asked him about starting treatment with daraxonrasib.

Getting them access is not as simple as writing a prescription for an FDA-approved drug, he and other cancer specialists said.

"Patients are already aware of the ​press release and are already calling," said Dr. ​Vincent Chung, pancreas cancer specialist at City ⁠of Hope. "The challenge now is how to proceed."

The program requires physicians to submit requests for each individual patient to Revolution Medicines, Chung said, and if the company decides they are a good candidate, all those details then need to be submitted to the FDA. Hospital monitoring boards will need to ​follow the patients.

"Given the volume, I am not sure what will happen on the FDA side. I'm sure they don't want to have 10,000 ​applications at once," Chung said, ⁠adding that the agency may instead set up a more general enrollment protocol.

Manji said his understanding is that cancer centers will not be required to collect detailed data on patients treated under the expanded access program, but will need to report serious side effects or other issues.

The FDA did not respond to a request for comment. The expedited voucher program was touted as a signature achievement by Dr. Marty Makary, who resigned ⁠as FDA Commissioner ​on Tuesday after weeks of clashes with Trump administration officials.

Around 67,000 people in the United States will be diagnosed, opens new tab with pancreatic ​cancer this year, and 53,000 will die of the disease, according to the American Cancer Society.

"We are doing this as a service to our patients," Chung said. "I'm hoping of course that the FDA is going to review the data and then ​there is an approval much sooner than is typical."

Reporting By Deena Beasley in Los Angeles and Nancy Lapid in Tucson; additional reporting by Julie Steenhuysen in Chicago; editing by Caroline Humer and Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Nancy has been a health news reporter and editor at Reuters for more than a decade, covering important medical research advances. She is the author of our twice-a-week Reuters Health Rounds newsletter.

GraniteShares has filed with the U.S. Securities and Exchange Commission to launch three new leveraged single-stock ETFs tied to high-volatility themes spanning nuclear energy, AI infrastructure and biotech.

• What’s going on with XE stock today?

The filing introduces the GraniteShares 2x Long XE Daily ETF, GraniteShares 2x Long MAIR Daily ETF and GraniteShares 2x Long RVMD Daily ETF, each designed to deliver 200% of the daily performance of their respective underlying stocks.

The filing highlights how issuers continue expanding beyond leveraged funds tied to mega-cap names such as Nvidia and Tesla, moving deeper into speculative and momentum-driven corners of the market.

GraniteShares also emphasized that the products are intended primarily for sophisticated investors and active traders capable of monitoring positions daily, underscoring the growing risks associated with leveraged single-stock products as retail demand for high-beta trades remains elevated.

Key Features Of The Proposed ETFs• Each fund seeks to provide 200% of the DAILY performance of its underlying stock.

• GraniteShares said the funds may use:

Swaps Deep in-the-money call options FLEX options Synthetic forwards Firect stock holdings •The issuer indicated swaps would likely serve as the primary mechanism for obtaining leveraged exposure.

• The filing says the funds are designed for active traders and investors who can monitor positions daily.

Ticker symbols have not been disclosed yet.

These ETFs arrive as markets lean harder into AI infrastructure expansion, nuclear power revival and biotech momentum trades, with data center energy demand and next-gen chip buildouts driving renewed interest in high-volatility thematic baskets. Leveraged single-stock products have also seen rising traction as traders increasingly rotate into "high-beta" expressions of structural themes rather than broad index exposure.

Photo: Shutterstock

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Expense ratios, yield, and sector breadth set these healthcare ETFs apart-see how their risk profiles and portfolio strategies compare.

Few cancers have proven as difficult to treat as pancreatic cancer, making any sign of a survival breakthrough a major event for both patients and investors.

Key Takeaways Revolution Medicines reported phase III data showing daraxonrasib cut death risk by 60% in PDAC.RVMD's daraxonrasib doubled median overall survival versus standard-of-care chemotherapy in the study.Revolution Medicines reported significant progression-free survival gains and a manageable safety profile. Shares of Revolution Medicines (RVMD - Free Report) were rising in pre-market today after the company reported full results from the phase III RASolute 302 study, which evaluated lead candidate daraxonrasib in previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC). These findings were also presented at the 2026 ASCO Annual Meeting yesterday and simultaneously published in the New England Journal of Medicine.

Though Revolution Medicines previously reported in April that the study met all primary and secondary endpoints based on interim analysis, the latest findings provide a more comprehensive look at the drug’s clinical benefit.

RVMD’s Detailed RASolute 302 Data Highlights Treatment AdvantageThe study enrolled a broad patient population, including those with diverse RAS mutations, particularly G12 variants, as well as those without identifiable RAS mutations. Participants were randomized to receive either 300 mg of oral daraxonrasib once daily or standard-of-care cytotoxic chemotherapy delivered intravenously. The primary endpoints included overall survival (OS) and progression-free survival (PFS) in patients with RAS G12-mutant tumors, while key secondary endpoints assessed these outcomes in the overall study population.

Across the RAS G12 population, daraxonrasib reduced the risk of death by 60% compared with standard chemotherapy and achieved a median OS of 13.2 months compared to 6.6 months for chemotherapy. The drug also demonstrated a significant benefit on PFS, with median PFS improving to 7.3 months from 3.5 months with chemotherapy.

Similar benefits were seen across the overall study population. Daraxonrasib reduced the risk of death by 60% and improved median OS to 13.2 months compared with 6.7 months for chemotherapy. Median PFS stood at 7.2 months for daraxonrasib versus 3.6 months with chemotherapy.

The drug was generally well-tolerated and demonstrated a manageable safety profile. Management noted that patients receiving daraxonrasib experienced meaningful improvements in patient-reported outcomes, including significant delays in the deterioration of cancer-related pain, overall global health status and quality of life.

Per Revolution Medicines, these findings strengthen daraxonrasib's potential to become a new treatment option for previously treated metastatic PDAC, a setting where effective therapies remain limited.

Based on the above data, the company intends to advance regulatory submissions globally. For the FDA submission, RVMD plans to use the Commissioner’s National Priority Voucher to significantly cut down the review period to just 1-2 months.

RVMD Stock’s Price PerformanceYear to date, the company’s shares have risen 98% compared with the industry’s nil growth.

Image Source: Zacks Investment Research

More on RVMD’s DaraxonrasibDaraxonrasib is designed to target a broad spectrum of RAS-driven cancers, including PDAC, non-small cell lung cancer (NSCLC) and colorectal cancer.

Apart from RASolute 302, Revolution Medicines is evaluating daraxonrasib for several other settings in PDAC. While the RASolute 303 study is assessing the drug for the first-line metastatic setting of the disease, the RASolute 304 study is evaluating its efficacy as an adjuvant therapy for patients with resectable PDAC.

Concerning NSCLC, the company is conducting the RASolve 301 study on daraxonrasib in patients with locally advanced or metastatic RAS-mutated NSCLC. It is on track to start a fifth late-stage study of the drug in the first-line NSCLC setting later this year.

To further strengthen its position in RAS-driven cancers, Revolution Medicines has established multiple clinical collaborations to evaluate daraxonrasib and its other RAS inhibitors in combination regimens. These partnerships include collaborations with Bristol Myers (BMY - Free Report) , Summit Therapeutics (SMMT - Free Report) and Tango Therapeutics (TNGX - Free Report) .

RVMD’s Zacks Rank

Revolution Medicines currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Revolution Medicines (RVMD +3.13%) looks unstoppable. The clinical-stage biotech company has been riding the wave of impressive clinical progress, sending its stock price up nearly 100% this year alone and about 285% over the past 12 months, as of this writing. The market clearly has high hopes for Revolution Medicines, but can the company live up to the expectations? Let's consider the bull and the bear case for this drugmaker.

The bull case: revolutionizing the cancer market Revolution Medicines focuses on developing drugs for RAS-addicted cancers. RAS is a family of proteins that act as molecular switches in controlling cell growth. They can be turned "on" or "off." In RAS-addicted cancers, mutations keep RAS stuck in the "on" position, and the cancer cells become dependent on that constant growth signal to proliferate. Revolution Medicines is targeting this category because it is a vast, high-unmet-need space. The company's targets include pancreatic cancer, colorectal cancer -- the second leading cause of cancer death in the world -- as well as the first on that list, lung cancer.

Image source: Getty Images.

Revolution Medicines may not have any products on the market, but its leading candidate, daraxonrasib, has already shown strong clinical trial results. In a phase 3 study that enrolled patients with previously treated metastatic pancreatic cancer, daraxonrasib posted an overall survival of 13.2 months, compared with 6.7 months for patients on chemotherapy. Being tested against the standard of care (not just against a placebo) in this study suggests that daraxonrasib could become the new standard of care in patients in this niche.

Revolution Medicines is running clinical trials for daraxonrasib in other indications, including a phase 3 study in non-small cell lung cancer (NSCLC). Revolution Medicines has other candidates as well. The company's zoldonrasib is being studied in NSCLC. Provided these candidates receive approval, Revolution Medicines could be looking at peak sales of well over $1 billion for both, if all goes well. For instance, some analysts predict that daraxonrasib could eventually generate $8.5 billion in revenue annually in the metastatic pancreatic cancer market alone. And if it earns approval across many other fields, it could peak at much higher levels than that. That's why the market is excited about Revolution Medicines' prospects.

Today's Change

(

3.13

%) $

4.67

Current Price

$

153.90

The bear case: What if something goes wrong? Revolution Medicines faces the same risks as other clinical-stage biotechs. The company generates no revenue and is consistently unprofitable. Clinical and regulatory setbacks with its leading candidate will sink the stock price. Further, Revolution Medicines is worth $33.6 billion. That's an almost unheard-of valuation for a clinical-stage biotech. By comparison, consider that Biogen, a well-established biotech company with a large drug portfolio and a solid pipeline, has a market cap of only $29.3 billion. So, the market thinks Revolution Medicines is worth about $4 billion more than Biogen.

On the one hand, it makes some sense. The market is, after all, forward-looking. And while Biogen has struggled in recent years and has a somewhat dim outlook, Revolution Medicines appears to have developed medicines that could establish dominant positions in one of the industry's largest therapeutic areas, typically dominated by pharmaceutical giants. The company's most advanced drug is significantly de-risked, too, having aced a phase 3 study on efficacy measures while showing a reasonable safety profile.

Still, at current levels, Revolution Medicines' success is already well-baked into the stock price, and any perceived issue will send its shares off a cliff. In other words, Revolution Medicines is a risky stock. My view is that interested investors should wait for a pullback before initiating a small position in the company and progressively add to it as the drugmaker continues to make clinical progress.

A diagnosis of pancreatic cancer is one of the most feared things in medicine. The disease has the highest mortality rate of all cancers. In 2026, roughly 67,530 Americans will be diagnosed with the disease in the U.S., and more than 52,740 will die from it, according to statistics from the Hirshberg Foundation for Pancreatic Cancer Research.

On May 31, Revolution Medicines (RVMD +3.13%) presented its Phase 3 trial findings for daraxonrasib, showing that this therapy, compared to chemotherapy, cut the risk of death by about 60% and more than doubled survival for patients with advanced pancreatic cancer.

It is the first time any drug has pushed median overall survival past the one-year threshold in a Phase 3 trial for metastatic pancreatic cancer. On hearing that news, oncologists at a conference gave Revolution a standing ovation.

It was a huge moment for the clinical-stage biotech. The stock is up more than 85% this year, as its name has been bandied about as a potential buyout target. Even if that doesn't happen because the stock's value has increased so much, the company is sitting on a very profitable drug.

There are three reasons why the stock remains a buy:

Image source: Getty Images.

1. There is a clear commercial runway for daraxonrasib Revolution Medicines is no longer just a distant pipeline story; it has entered the pre-commercial execution phase. After releasing the data, the company is advancing a rolling New Drug Application (NDA) submission for daraxonrasib with the Food and Drug Administration (FDA).

The FDA has already approved an Expanded Access Program for daraxonrasib, creating massive immediate demand from major U.S. cancer centers rushing to secure the drug for terminal patients ahead of official commercialization. The drug works by blocking the RAS protein, which drives tumor growth in more than 90% of pancreatic cancer cases, as well as other cancers.

Just having the treatment for pancreatic cancer is worth billions, but the drug is also being tested as a therapy to treat other RAS-addicted cancers, including certain colorectal and non-small cell lung cancers.

Today's Change

(

3.13

%) $

4.67

Current Price

$

153.90

2. Revolution has a diverse, plural pipeline Biotech investing is notoriously risky when a company relies on a single asset. Revolution mitigates that problem with a portfolio of RAS inhibitors addressing different mutations and indications.

Besides daraxonrasib, the company is advancing zoldonrasib (RMC-9805) for KRAS G12D mutants (showing highly encouraging initial data in non-small cell lung cancer) and elironrasib (RMC-6291), targeting KRAS G12C mutations.

The science behind the company's therapies is the ability to use its platform to block oncogenic signaling by RAS(ON) proteins, which are traditionally difficult targets. The company designs molecules that bind to the "chaperone protein" cyclophilin A, forming an interface that can be tailored to bind to different RAS(ON) proteins.

3. Revolution has a big cash stockpile and takeover possibilities Revolution isn't profitable. In the first quarter, the company reported a loss of $453.8 million. However, the company has roughly $4 billion in cash and short-term investments. At its current burn rate, it has two years to bring daraxonrasib to market without needing to dilute shareholders with late-stage capital raises.

That gives the company flexibility to go it alone, using daraxonrasib sales to fund its development, or court larger pharmaceutical companies that would love to buy out Revolution for the opportunity to inherit its platform.

Revolution backed away from a buyout deal from Merck in January that would have valued Revolution at between $28 billion and $32 billion. It's easy to see now why, as the stock's market cap is already over $32 billion. There are other pharmaceutical giants with drugs facing patent cliffs that could pursue a takeover of Revolution.

Revolution Medicines has great potential with some risk Revolution is the classic high-risk, high-reward biotech stock. If daraxonrasib doesn't come to market by the end of the year, the stock could easily plunge. It's important to note that the ability to develop a successful drug is a different skill set from running a successful company.

There's plenty of reason for optimism here. The stock, even after the run-up, is trading at around $148 per share, well below analysts' average price targets, which range between $165 and $182.

It remains a high-conviction play purely on execution, commercial rollout, and potential future interest from larger pharma suitors looking to bolster their oncology pipelines.